GlycoMimetics (NASDAQ:GLYC) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Posted by ABMN Staff on Mar 23rd, 2025

Research analysts at Cantor Fitzgerald began coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Free Report) in a report issued on Friday, Marketbeat.com reports. The firm set an “overweight” rating on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on GlycoMimetics in a research note on Friday, March 14th. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, GlycoMimetics has a consensus rating of “Hold” and an average price target of $8.00.

Get Our Latest Research Report on GLYC

GlycoMimetics Stock Down 0.5 %

NASDAQ GLYC opened at $0.27 on Friday. The stock’s 50-day moving average is $0.27 and its 200-day moving average is $0.26. GlycoMimetics has a one year low of $0.14 and a one year high of $3.18.

GlycoMimetics (NASDAQ:GLYC – Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. On average, equities research analysts forecast that GlycoMimetics will post -0.08 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jefferies Financial Group Inc. bought a new position in shares of GlycoMimetics during the 4th quarter worth approximately $106,000. VR Adviser LLC bought a new position in shares of GlycoMimetics during the 4th quarter worth approximately $747,000. Caxton Corp bought a new position in shares of GlycoMimetics during the 4th quarter worth approximately $51,000. Adage Capital Partners GP L.L.C. bought a new position in shares of GlycoMimetics during the 4th quarter worth approximately $1,268,000. Finally, Wellington Management Group LLP bought a new position in shares of GlycoMimetics during the 4th quarter worth approximately $352,000. 75.19% of the stock is currently owned by institutional investors.

GlycoMimetics Company Profile

(Get Free Report)

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.